Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Ruxolitinib for treatment of CRS in R/R AML treated with flotetuzumab

John DiPersio • 8 Dec 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Antibodies CAR-T Flotetuzumab Ruxolitinib

John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, outlines the results of a study investigating prophylactic ruxolitinib for the treatment of cytokine release syndrome (CRS) in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with flotetuzumab. The study found that prophylactic ruxolitinib produced a clear difference in cytokine profiles but no discernible improvement in clinical CRS or response rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from John DiPersio

One big question with John DiPersio: what AML advance could transform frontline care in three years?
2:06
One big question with John DiPersio: what AML advance could transform frontline care in three years?
John DiPersio • 26 Sep 2025
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
3:30
Insights into WU-CART-007: an off-the-shelf CAR-T therapy for T-cell malignancies
John DiPersio • 19 Sep 2025
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
1:14
Risk factors for CRS and ICANS in patients receiving CAR T-cell therapy
John DiPersio • 19 Sep 2025
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
2:23
Strategies for CRS prophylaxis in patients treated with CAR-T: beyond tocilizumab and anakinra
John DiPersio • 19 Sep 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals